Remove Pricing Remove San Diego Remove Silver Lake Remove Venture Capital
article thumbnail

Bio Roundup: $74B for Celgene, Two CAR-T Tales, Ready for SF & More

Xconomy

Topics ranged from the worries over CRISPR genome editing and Wild West biohacking, to Nobel Prize-fueled drug approvals and the headaches around drug prices (even for drugs meant to cure headaches). You’ll find a few of our favorite stories in this review of some of the year’s best from across the Xconomy network.

Pricing 69